Recent News

JAVELIN Medley VEGF: Monoclonal Antibody Plus VEGFR Inhibitor Studied in NSCLC

FDA Brief: Zenocutuzumab Granted Fast Track Designation for NRG1 Fusion Cancers

Biomarker May Predict Susceptibility to Radiation Pneumonitis in Patients With Lung Cancer

Tiragolumab Combination Treatment Granted Breakthrough Therapy Designation in NSCLC

Can Chemoimmunotherapy Achieve Pathologic Downstaging in Resectable Lung Cancer?

Lorlatinib Receives Priority Review in Untreated ALK-Positive Lung Cancer

Adjuvant Osimertinib Approved by FDA for EGFR-Mutated Lung Cancer

Individualized Versus Standard Dosing of Radiotherapy in Stage III NSCLC

Stereotactic Body Radiotherapy for Larger Lung Tumors

First-Line Pembrolizumab Plus Niraparib in Advanced Metastatic NSCLC

Ramucirumab Plus Osimertinib in NSCLC: Final Analysis of Phase I Trial

Novel Immune Checkpoint Inhibitor Under Study in Advanced NSCLC

Targeting KRAS Mutations in Advanced NSCLC: Early Trial Results

Capmatinib in MET-Dysregulated Advanced NSCLC: GEOMETRY Mono-1

ESMO Asia 2020: Adding PD-L1 Inhibitor to Platinum-Based Chemotherapy for NSCLC

Lorlatinib for First-Line Treatment of ALK-Positive NSCLC

SITC 2020: Bemcentinib and Pembrolizumab in Stage IV Lung Adenocarcinoma

SITC 2020: Vactosertib Plus Durvalumab in PD-L1–Positive NSCLC

ASTRO 2020: Pericardial Effusion and Survival With Radiation Therapies in Locally Advanced NSCLC

Timing of Brain Radiotherapy for NSCLC With Brain Metastasis

ASTRO 2020: Stereotactic Body Radiotherapy With and Without Pembrolizumab Under Study in Lung Cancer

Equivalence Study of Bevacizumab Biosimilar in Metastatic Nonsquamous NSCLC

ASTRO 2020: Cardiac Events With Photon Versus Proton Radiotherapy for Lung Cancer

Lung Cancer and Severity of COVID-19: Experience From MSK

Osimertinib Receives Priority Review for EGFR-Mutant NSCLC

Early Clinical Data on Sotorasib in Advanced NSCLC

Treatment Duration for Nivolumab in Advanced NSCLC: CheckMate 153

ESMO 2020: Does Immune Oncology Increase the Risk of SARS-CoV2–Related Mortality in NSCLC?

ESMO 2020: Pembrolizumab Versus Docetaxel in Subgroup of Patients With NSCLC

ESMO 2020: Vinorelbine Plus Atezolizumab in Recurrent Stage IV Lung Cancer

ESMO 2020: First-Line Pembrolizumab, Chemotherapy, and Lenvatinib in Metastatic NSCLC

Study Supports Use of RET Inhibitor in RET Fusion–Positive Lung Cancer

ESMO 2020: CNS Recurrence Patterns With Osimertinib in Treatment of NSCLC

ESMO 2020: Is Neoadjuvant Atezolizumab Safe in Patients With Resectable NSCLC?

ESMO 2020: Combining Ipilimumab With PD-1 Blockade in Advanced Lung Cancer

ESMO 2020: Lorlatinib Versus Crizotinib in First-Line Treatment of ALK-Positive NSCLC

ESMO 2020: Is Routine Postoperative Radiotherapy in NSCLC With Mediastinal Nodes of Benefit?

COVID-19 and Lung Cancer: Skin Manifestations With Immunotherapy

Are ‘Light’ Smokers at Increased Risk of Death From Lung Cancer?

FDA Brief: Pemetrexed Injection Receives FDA Approval for Lung Cancer

Pralsetinib Approved by FDA for Metastatic RET Fusion–Positive NSCLC

Survival Outcomes in Lung Cancer in the United Kingdom During the COVID-19 Pandemic

COVID-19 and Thoracic Cancer: First Results From TERAVOLT

Liquid Biopsy Companion Diagnostic Test Approved for Metastatic NSCLC

Lung Cancer and COVID-19: Global Experts Offer Treatment Guidance

Does Nicotine Promote Brain Metastasis of Lung Cancer?

FDA Grants Priority Review for New Durvalumab Dosing Regimen in NSCLC

AACR COVID-19: SRMS Expression in Patients With Lung Cancer

WCLC 2020: Ensartinib Versus Crizotinib in First-Line Treatment of ALK-Positive NSCLC

AACR COVID-19: Changes in Lung Cancer Management

WCLC 2020: Adding Sintilimab to Chemotherapy for Nonsquamous NSCLC

Phase I Trial of Combined MEK and EGFR Inhibition in NSCLC

COVID-19 and Lung Cancer: Proactive Measures for Screening Patients

Osimertinib Given Breakthrough Therapy Designation for EGFR-Mutated Lung Cancer

ctDNA Clearance and Savolitinib Plus Osimertinib in MET-Amplified Lung Cancer

Survival Update With Bevacizumab Plus Erlotinib in Certain Patients With NSCLC